Business
Lunai Bioworks (NASDAQ: LNAI) Expands NIH-Funded AI Program into Commercial Alcohol Use Disorder Drug Discovery
Lunai Bioworks (NASDAQ: LNAI), an AI-powered drug discovery and biodefense company, today announced it has completed a key commercial milestone under its NIH STTR-supported initiative, generating high-resolution, multidimensional behavioral signatures of ethanol exposure and alcohol withdrawal. Using high-throughput vertebrate screening, the company identified distinct, reproducible neurobehavioral phenotypes that are only partially addressed by currently approved therapies, highlighting previou
About this update from Lunai Bioworks Inc.
[{"type":"text","content":"AI Platform Achieves Key Milestones, Triggering Launch of Alcohol Use Disorder Program","length":86,"tagName":"p"},{"type":"text","content":"SACRAMENTO, Calif. , Jan. 26, 2026 /PRNewswire/ -- Lunai Bioworks (NASDAQ: LNAI), an AI-powered drug discovery and biodefense company, today announced it has completed a key commercial milestone under its NIH STTR-supported initiative, generating high-resolution, multidimensional behavioral signatures of ethanol exposure and alcohol withdrawal. Using high-throughput vertebrate screening, the company identified distinct, reproducible neurobehavioral phenotypes that are only partially addressed by currently approved therapies, highlighting previously underexplored biological mechanisms with strong translational potential. Based on these results, the company has initiated a new commercial drug discovery program targeting Alcohol Use Disorder (AUD), a condition affecting approximately 30 million individuals in the U.S. alone, with over 95% receiving no effective pharmacologic treatment.","length":910,"tagName":"p"},{"type":"image","alt":"Lunai Bioworks Inc. (PRNewsfoto/Lunai Bioworks Inc.)","displaySize":"","headline":null,"caption":"Lunai Bioworks Inc. (PRNewsfoto/Lunai Bioworks Inc.)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":123,"url":"https://media.zenfs.com/en/prnewswire.com/e1394d131f94f2906bb3fbc63140be9f"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/PR3.Qv1zkg2N7mzYMfWyzw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTIxNztjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/e1394d131f94f2906bb3fbc63140be9f","width":400,"height":123}},"href":"https://mma.prnewswire.com/media/2814530/Lunai_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"Lunai's AUD program is designed to advance differentiated, mechanism-informed therapeutic candidates toward clinical translation, while remaining strategically positioned for partnerships, licensing, and non-dilutive funding opportunities. With scalable screening infrastructure now operational, the company believes the program can rapidly progress toward candidate nomination and downstream development.","length":409,"tagName":"p"},{"type":"text","content":""These results underscore both the magnitude of unmet need in Alcohol Use Disorder and the commercial opportunity...